Advantis Corp. Announces Negotiations With Major Retail Chain

IRVINE, CA--(Marketwired - Dec 7, 2015) - Advantis Corporation (OTC PINK: ADVT) has announced its imminent finalization of signing a deal with a major retail chain.

On the dawn of officially changing its name and signing its first exclusive distribution agreement with LipMedRX, LLC, Advantis Corp. announced it is at the tail-end of rapping up an agreement with a major retail chain, while also successfully reducing its debt by over $400,000.

According to Advantis Corp.'s Vice President, Geoffrey Broderick, "First we have what is the first ground breaking cold and flu preventive product in the lip balm industry, then we achieved the execution of a deal to have Advantis be the exclusive distributer, and now we have taken the ultimate step of successfully lining up a major retail chain to launch LipMed Rx!" Broderick continued, "As you may already know, we recently decided to launch a LipMedRx west coast headquarters here in our 16000 SF Irvine office in order to keep a close eye on all the progress."

Broderick concluded, "This great news reflects one of the many steps Advantis has been taking to help build shareholder value by timing the core Advantis rebranding process to coincide with the imminent finalization of several agreements which will no doubt welcome Advantis to the next level. This focus on shareholder value is starting to become apparent, as recent financials reflect a strong reduction in long-term liabilities by over 400k. We should all look forward to a very successful 2016!"

A recent press release from LipMedRx, LLC stated it just launched a new anti-germ, lip balm protectant that studies have shown to be highly effective in killing those germs associated with cold and flu on the lips before they enter the mouth. The Anti-Flu & Cold Lip Balm Protectant is the first ever lip balm that kills germs on the lips before they can enter the body. The product was designed to not only provide protection from germs but also be a moisturizing agent that keeps lips soft and smooth. Advantis Corp. CEO, Jeremy Foti, stated in a recent press conference, "Our new beginning has arrived...this is just one of several deals that we are working on under our new medical division, but we are very excited with the progress that has been made since we have put the new team in place."

ABOUT Advantis Corporation
Advantis Corporation (ADVT) focuses on the development of innovative products that supply the medical, research, and pharmaceutical industries. In addition, the company is establishing domestic and international partnerships with businesses that develop and sell proprietary consumer products and services. Product lines for consumer health care, music and entertainment sectors are in development.

Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward- looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward- looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act.